One payer-region pocket and exactly three named accounts under a bounded pilot.
NextConsensus · sample work
Governed decision-review packet · redacted excerpt for sponsor-side circulation
Document control
NC-SPEC-CR-04
Public-safe composite / Print circulation
Cardiorenal Access Ratification Memo (Redacted Excerpt)
A forwarding-format packet designed to make one bounded access decision legible: why the criteria changed, who needs to sign, what gets piloted now, and what triggers pause or rollback before the pilot widens.
3 accounts / 120 days
One therapy class, one payer-region pocket, no spillover to non-pilot criteria.
5-step sign-off
Brand Strategy, HEOR, Medical/MLR, Legal, and Procurement before activation.
Weekly guardrail review
Two breaches in 14 days pauses the pilot within one business day.
Why this reads like repeatable work
Public-safe packet lineage rather than one-off memo polish.
Reused core
Threshold and signer frame
The recommendation, review cadence, and rollback test are carried from prior governed packet logic.
Localized layer
Account and region delta
Only the payer-region criteria, named accounts, and adjudication exceptions change in this version.
Write-back layer
What becomes memory
Acceptance state, pause reasons, and the next review trigger are written back after the pilot closes.
Pilot envelope and review cadence
Illustrative structure preserved from the specimen packet.
Day 0
Signers locked, procurement terms executed, and the three-account list frozen.
Day 14
Weekly safety and utilization review begins alongside first adjudication checks.
Day 45
Leakage and cycle-time read is used to hold, narrow, or continue the pilot unchanged.
Day 120
Scale, sunset, or reset to legacy criteria with committee re-review and documented recourse.
1) Concrete problem framing
Prior-authorization criteria in [payer region A] are still aligned to legacy evidence and are now misaligned with the current risk profile in [high-risk cohort]. Delay is visible as slower appropriate starts and avoidable acute utilization leakage.
2) Explicit recommendation
Approve a bounded local override for exactly three accounts. Apply updated entry criteria from the governance packet and leave all non-pilot account criteria unchanged during the window.
3) Decision-owner path
Owner initiates packet sign-off through Brand Strategy -> HEOR -> Medical/MLR -> Legal -> Procurement. Activation requires written approval from Medical/MLR and Legal plus executed pilot procurement terms.
4) Safeguards and rollback
Safety and utilization guardrails are reviewed weekly. If any guardrail breaches twice in a rolling 14-day period, pilot logic is paused within one business day and reverts to legacy criteria until committee re-review.
5) What changes next week vs later
Next week: finalize signers, lock pilot accounts, run checklist training, and adjudicate first cases.
Later (day 45-120): review leakage, cycle-time, and safety outcomes to scale, narrow, or sunset.
Simulated decision-impact view
Illustrative public-safe scenario, not live production data.
Illustrative median time to appropriate start moves from 18 days to 8 days.
Flagged acute-utilization leakage declines from 14 cases per month to 6 inside the window.
No illustrative weekly review crosses the pause threshold required for rollback.
The point is not precision theater. It is whether the packet makes the monitored change and the recourse visible in one glance.
Three-account operating view
Simulated review statuses inside the bounded pilot.
Account A · ready for activation
Training complete, signer packet closed, and first adjudications queued.
Ready
Current stage
Activation lane
Account B · utilization watch
Override active with weekly review after one higher-than-expected denial cluster.
Review
Current stage
Guardrail review
Account C · signer hold
Procurement terms drafted; no activation until Medical/MLR and Legal confirm language.
Hold
Current stage
Signer completion
A bounded packet should make it obvious which accounts can move, which need re-review, and which cannot activate yet.
Source page: nextconsensus.com/work-product/#specimen-decision-memo